Spacelabs Healthcare Introduces the qubeMonitor

ISSAQUAH, Wash.--()--Having received clearance under Section 510(k) from the U.S. Food and Drug Administration, Spacelabs Healthcare is adding the qube patient monitor to its Art of Monitoring portfolio. Inspired by the revolutionary style of the company’s XPREZZON™ patient monitor, qube breaks with tradition to offer a fresh, new perspective in compact monitoring.

Small and lightweight – with a battery life that goes the distance – qube offers portability, accessibility and heightened connectivity – perfect for emergency, general/step-down, and post-anesthesia care units. qube is mountable anywhere – wall, bedrail, anesthesia system – and can be detached via a quick-release feature, for immediate mobility. Caregivers can access current, critical patient information, from bedside throughout transport, to provide the ultimate level of patient care.

“Through the optimal blend of art and technology, qube is designed to create a patient-friendly experience while providing the caregiver with full functionality, accessibility and portability in a compact package,” said Nicholas Ong, President of Spacelabs Healthcare.

THE ART OF MONITORING

Spacelabs.The_Art_of_Monitoring_small
Spacelabs.The_Art_of_Monitoring_med
Spacelabs.The_Art_of_Monitoring_large

About Spacelabs Healthcare, Inc.

Spacelabs Healthcare, Inc. (www.spacelabshealthcare.com), a wholly-owned subsidiary of OSI Systems, Inc., is an international developer, manufacturer and distributor of medical equipment and services including solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories selling to hospitals, clinics and physician offices. The Company has offices in the United States, United Kingdom, Canada, France, Germany, Italy, China, India and Singapore and distribution partners in more than 100 countries around the world.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include information regarding the Company’s expectations, goals or intentions about the future, including, but not limited to, statements regarding the performance of the Company’s patient monitoring products. The actual results may differ materially from those described in or implied by any forward-looking statement. Other important factors are set forth in the Securities and Exchange Commission filings of OSI Systems, Inc. All forward-looking statements speak only as of the date made, and we undertake no obligation to update these forward-looking statements.

Contacts

Spacelabs Healthcare
Ross Garland, 425-657-7200 x4000
ross.garland@spacelabs.com

Sharing

Contacts

Spacelabs Healthcare
Ross Garland, 425-657-7200 x4000
ross.garland@spacelabs.com